Reducing Timelines And Development Costs Through Predictable Bioreactor Scale Up Using The Xcellerex™ X Platform Bioreactor

Time to market and process economics are key drivers for drug manufacturing. Multi-batch scale-up runs delays and increases the cost of transferring R&D processes to manufacturing. Reproducible and predictable performance across bioreactor scales supports technology transfer and commercialization, reducing timelines and cost.

Bioreactor design is critical for enabling predictable cell culture scale‑up, through the selection of well‑defined engineering parameters to provide consistent hydrodynamics, mass transfer, and process performance across scales. In particular, the application of constant power input per volume (P/V) and a defined gassing strategy can reduce the need for iterative, intermediate‑scale experimentation, thereby accelerating development timelines and lowering the cost of development.

The Xcellerex X‑platform bioreactor has been geometrically scaled across the range to support the application of common scale‑up criteria from 50 to 2000 L. The platform incorporates a sparger design that enables comparable mass transfer performance when scaling using constant volumetric gas flow (VVM), allowing consistent mixing and oxygen transfer across vessel sizes.

In this study, a single, engineering‑based scale‑up strategy was applied to two distinct cell culture processes to demonstrate platform scalability and manufacturability. A Chinese Hamster Ovary (CHO) fed‑batch process producing an IgG monoclonal antibody was scaled from X‑50 to X‑500 and X‑2000 using a constant P/V and VVM. Comparable cell growth, metabolite profiles, and product title were achieved across all scales, demonstrating predictable scale-up. A second cell line and process, a Spodoptera frugiperda (Sf9) batch process focused on cell growth was scaled from another suppliers 3 L bench‑top to the X‑50 using the same scale‑up principles, resulting in comparable growth and metabolic profiles. These results demonstrate that engineering‑driven bioreactor design and parameter selection enables predictable scale‑up, independent of bioreactor system and cell line to the X-platform. The ability to apply a defined scale‑up strategy across processes and volumes reduces development complexity, shortens timelines, and supports robust transfer to manufacturing, providing a clear pathway to improved process economics and commercial readiness.